PSA density is strongly associated with pathological stage and biochemical-free survival after radical prostatectomy for prostate cancer, researchers conclude. In lower grade prostate cancers (biopsy ...
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
Automated prostate lesion detection and PI-RADS assessment with deep learning. The relative contributions of the Genomic Prostate Score and comorbidity profile in predicting outcomes in surgically ...
The clinical outcome of second generation anti-hormonal therapy in patients with metastatic castrate-resistant prostate cancer following CHAARTED regimen. This is an ASCO Meeting Abstract from the ...
In the wake of more than a decade of controversy over PSA testing, research is emerging that points to new approaches for the stratification of prostate cancer risk. Two noninvasive tests — an ...
The European Society for Medical Oncology has updated its clinical practice guidelines for the management of localised prostate cancer and biochemical recurrence, refining diagnostic pathways and ...
September is Prostate Cancer Awareness Month. The COVID-19 pandemic continues to lead to unacceptable morbidity and mortality rates in the Bahamas. Approximately 100 men die every year in the Bahamas ...
Prostate specific antigen (PSA) is a type of protein released by the prostate gland. Screening for possible prostate cancer involves taking a PSA blood test, which is recommended annually starting at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results